停用核苷(酸)类似物后伴肝失代偿的严重肝炎 flare:一项基于人群的队列研究
这项基于人群的队列研究纳入10,192例停用一线核苷(酸)类似物(NUC)的慢性乙型肝炎患者,中位随访2.2年,132例发生伴肝失代偿的严重flare,4年累积发生率1.8%(95%CI 1.5%-2.2%);无肝硬化和门脉高压者(n=8863)为1.3%(95%CI 1.0%-1.7%),符合标准停药规则者(n=1274)为1.1%(95%CI 0.6%-2.0%)。危险因素包括高龄、肝硬化、门脉高压和男性。作者结论反对将停用NUC作为常规临床诊疗的一部分。
要点
- 停用NUC后伴肝失代偿的严重flare 4年累积发生率为1.8%(95%CI 1.5%-2.2%)。
- 无肝硬化和门脉高压者4年累积发生率为1.3%(95%CI 1.0%-1.7%)。
- 肝硬化(aSHR 2.74)、门脉高压(aSHR 2.46)、高龄(每10年aSHR 1.21)和男性(aSHR 1.58)为危险因素。
核心结论
- 日常实践中停用NUC后约1%-2%的慢性乙型肝炎患者发生伴肝失代偿的严重flare,作者结论反对将停用NUC作为常规临床诊疗的一部分。
研究设计与样本
- 基于人群的队列研究,纳入10,192例曾接受一线NUC治疗至少1年后停药的患者(男性71.7%,中位年龄50.9岁,肝硬化10.7%)。
- 采用竞争风险分析评估事件发生率和相关危险因素,中位随访2.2年。
主要发现
- 中位随访2.2年期间132例发生伴肝失代偿的严重flare,4年累积发生率为1.8%(95%CI 1.5%-2.2%)。
- 危险因素包括肝硬化(aSHR 2.74;95%CI 1.82-4.12)、门脉高压表现(aSHR 2.46;95%CI 1.45-4.18)、年龄(每10年aSHR 1.21;95%CI 1.03-1.42)和男性(aSHR 1.58;95%CI 1.04-2.38)。
- 无肝硬化或门脉高压的患者(n=8863)4年累积发生率为1.3%(95%CI 1.0%-1.7%)。
- 有数据确认遵守标准停药规则的患者(n=1274)发生率为1.1%(95%CI 0.6%-2.0%)。
临床怎么用
- 作者结论反对将停用NUC作为常规临床诊疗的一部分。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Finite nucleos(t)ide analogue (NUC) therapy has been proposed as an alternative treatment strategy for chronic hepatitis B (CHB). AIM: To quantify the incidence of severe hepatitis flares following NUC cessation in everyday clinical practice. METHODS: This population-based cohort study enrolled 10,192 patients (male 71.7%, median age 50.9 years, cirrhosis 10.7%) who had received first-line NUCs for at least 1 year before discontinuing treatment. The primary outcome was severe flare with hepatic decompensation. We used competing risk analyses to assess event incidences and associated risk factors. RESULTS: During a median follow-up of 2.2 years, 132 patients developed severe flares with hepatic decompensation, yielding a 4-year cumulative incidence of 1.8% (95% confidence interval [CI], 1.5%-2.2%). Significant risk factors were cirrhosis (adjusted sub-distributional hazard ratio [aSHR], 2.74; 95% CI, 1.82-4.12), manifestations of portal hypertension (aSHR, 2.46; 95% CI, 1.45-4.18), age (aSHR, 1.21 per 10 years; 95% CI, 1.03-1.42) and male sex (aSHR, 1.58; 95% CI, 1.04-2.38). In patients without cirrhosis or portal hypertension (n = 8863), the 4-year cumulative incidence of severe withdrawal flares stood at 1.3% (95% CI, 1.0%-1.7%). For those patients with available data confirming adherence to the standard stopping rules (n = 1274), the incidence was 1.1% (95% CI, 0.6%-2.0%). CONCLUSIONS: Severe flares with hepatic decompensation were observed in 1%-2% of patients with CHB after stopping NUC therapy in daily practice. Risk factors included older age, cirrhosis, portal hypertension and male sex. Our findings argue against NUC cessation as part of routine clinical care.
引用
- Hsu YC, Lin YH, Lee TY, et al. Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos(t)ide analogues: A population-based cohort study. Aliment Pharmacol Ther. 2023. PMID: 37341016. doi:10.1111/apt.17614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。